Date: 2018-09-06
Type of information: Research agreement
Compound: new formulations for anti-infective products
Company: Leukocare (Germany) Xellia Pharmaceuticals (Denmark)
Therapeutic area: Infectious diseases
Type agreement: research - development - R&D
Action mechanism:
Disease:
Details:
- • On September 6, 2018, Leukocare and Xellia Pharmaceuticals, a specialty pharmaceutical company providing important anti-infective treatments against serious and often life threatening infections, announced a global strategic partnership to discover innovative formulations which will enable the development of value-added anti-infective products intended to enhance patient care.
- Under the agreement, Leukocare will work closely with Xellia’s team of product development experts and apply its proprietary SPS® (Stabilizing and Protecting Solutions) formulation technology platform to discover novel liquid formulations for multiple anti-infective products that will expand Xellia’s portfolio of innovative products. Xellia will have access to Leukocare´s proprietary SPS® formulation technology platform to be used for its antibiotic and antifungal product portfolio.
Financial terms:
- Leukocare will receive annual license fees, formulation development funding, plus royalties on future product sales. Further financial terms of this deal have not been disclosed
Latest news:
Is general: Yes